BRAF and cutaneous melanoma: On the one hand, we have three combinations of targeted therapies (TT) with BRAF-MEK inhibitors (dabrafenib-trametinib, vemurafenib-cobimetinib, and encorafenib-binimetinib) in patients with a BRAF mutation (50% of all subtypes of cutaneous melanoma).